<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37732336</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2222-1751</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Emerging microbes &amp; infections</Title><ISOAbbreviation>Emerg Microbes Infect</ISOAbbreviation></Journal><ArticleTitle>A follow-up study on the recovery and reinfection of Omicron COVID-19 patients in Shanghai, China.</ArticleTitle><Pagination><StartPage>2261559</StartPage><MedlinePgn>2261559</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2261559</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/22221751.2023.2261559</ELocationID><Abstract><AbstractText>Limited follow-up data is available on the recovery of Omicron COVID-19 patients after acute illness. It is also critical to understand persistence of neutralizing antibody (NAb) and of T-cell mediated immunity and the role of hybrid immunity in preventing SARS-CoV-2 reinfection. This prospective cohort study included Omicron COVID-19 individuals from April to June 2022 in Shanghai, China, during a large epidemic caused by the Omicron BA.2 variant. A total of 8945 patients from three medical centres were included in the follow up programme from November 2022 to February 2023. Of 6412 individuals enrolled for the long COVID analysis, 605 (9.4%) individuals experienced at least one sequelae, mainly had fatigue and mental symptoms specific to Omicron BA.2 infection compared with other common respiratory tract infections. During the second-visit, 548 (12.1%) cases of Omicron reinfection were identified. Hybrid immunity with full and booster vaccination had reduced risk of SARS-CoV-2 reinfection by 0.29-fold (95% CI: 0.63-0.81) and 0.23-fold (95% CI: 0.68-0.87), respectively. For 469 participants willing to the hospital during the first visit, those who received full (72 [IQR, 36-156]) or booster (64 [IQR, 28-132]) vaccination had significantly higher neutralizing antibody titers than those with incomplete vaccination (36 [IQR, 16-79]). Moreover, non-reinfection cases had higher neutralizing antibody titers (64 [IQR, 28-152]) compared to reinfection cases (32 [IQR, 20-69]).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Mengna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Institute of Infectious Disease and Biosecurity, School of Public Health, Fudan University, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Kangli</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Clinical Center for Bio-Therapy, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Feixiang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xueling</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Renji hospital, Shanghai jiaotong University, School of medicine, 160 Pujian Road, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Yao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, Shanghai Pudong Hospital, Fudan University, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Su</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuang</LastName><ForeName>Zhongshu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Hailin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Shuyun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shao</LastName><ForeName>Mian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Guorong</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xing</LastName><ForeName>Lingyu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Tianwen</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Shaodie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Jiamin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiaoyan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Clinical Center for Bio-Therapy, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yilin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Guoping</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Genetic Engineering, Fudan Microbiome Center, School of Life Sciences, Fudan University, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bio-Med Big Data Center, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Lihong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jianqing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clinical Center for Bio-Therapy, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Institute of Infectious Disease and Biosecurity, School of Public Health, Fudan University, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Zhenju</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Institute of Infectious Disease and Biosecurity, School of Public Health, Fudan University, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Key Laboratory of Lung Inflammation and Injury, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Emerg Microbes Infect</MedlineTA><NlmUniqueID>101594885</NlmUniqueID><ISSNLinking>2222-1751</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000084063" MajorTopicYN="N">Reinfection</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">T-cell responses</Keyword><Keyword MajorTopicYN="N">inactivated vaccination</Keyword><Keyword MajorTopicYN="N">neutralizing antibody</Keyword><Keyword MajorTopicYN="N">reinfection</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>21</Day><Hour>4</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37732336</ArticleId><ArticleId IdType="pmc">PMC10563605</ArticleId><ArticleId IdType="doi">10.1080/22221751.2023.2261559</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Evans RA, McAuley H, Harrison EM, et al. . Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. The Lancet Respiratory Medicine. 2021 Nov;9(11):1275&#x2013;1287. doi:10.1016/S2213-2600(21)00383-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00383-0</ArticleId><ArticleId IdType="pmc">PMC8497028</ArticleId><ArticleId IdType="pubmed">34627560</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Burden of Disease Long CC, Wulf Hanson S, Abbafati C, et al, et al. . Estimated global proportions of individuals With persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. Jama. 2022 Oct 25;328(16):1604&#x2013;1615. doi:10.1001/jama.2022.18931</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.18931</ArticleId><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigfrid L, Drake TM, Pauley E, et al. . Long COVID in adults discharged from UK hospitals after COVID-19: a prospective, multicentre cohort study using the ISARIC WHO clinical characterisation protocol. The Lancet Regional Health Europe. 2021 Sep;8:100186. doi:10.1016/j.lanepe.2021.100186</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100186</ArticleId><ArticleId IdType="pmc">PMC8343377</ArticleId><ArticleId IdType="pubmed">34386785</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, et al. . Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022 Aug;28(8):1706&#x2013;1714. doi:10.1038/s41591-022-01909-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01909-w</ArticleId><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson KB, Rao M, Bonilla H, et al. . Patients With uncomplicated coronavirus disease 2019 (COVID-19) have long-term persistent symptoms and functional impairment similar to patients with severe COVID-19: A cautionary tale during a global pandemic. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2021 Aug 2;73(3):e826&#x2013;e829. doi:10.1093/cid/ciab103</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab103</ArticleId><ArticleId IdType="pmc">PMC7929039</ArticleId><ArticleId IdType="pubmed">33624010</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballering AV, van Zon SKR, Hartman O, et al. . Persistence of somatic symptoms after COVID-19 in The Netherlands: an observational cohort study. Lancet. 2022 Aug 6;400(10350):452&#x2013;461. doi:10.1016/S0140-6736(22)01214-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01214-4</ArticleId><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, et al. . Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. 2022 Jun 18;399(10343):2263&#x2013;2264. doi:10.1016/S0140-6736(22)00941-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00941-2</ArticleId><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Baskett WI, Qureshi AI, Shyu D, et al. . COVID-Specific Long-term sequelae in comparison to common viral respiratory infections: An analysis of 17 487 infected adult patients. Open Forum Infect Dis. 2023 Jan;10(1). ofac683. doi:10.1093/ofid/ofac683</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac683</ArticleId><ArticleId IdType="pmc">PMC9846186</ArticleId><ArticleId IdType="pubmed">36686632</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang WQ, Li XS, Zhong WH, et al. . Comparison of clinical characteristics in patients with coronavirus disease and influenza A in Guangzhou, China. World J Emerg Med. 2021;12(4):287&#x2013;292. doi:10.5847/wjem.j.1920-8642.2021.04.006</Citation><ArticleIdList><ArticleId IdType="doi">10.5847/wjem.j.1920-8642.2021.04.006</ArticleId><ArticleId IdType="pmc">PMC8390343</ArticleId><ArticleId IdType="pubmed">34512825</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilz S, Theiler-Schwetz V, Trummer C, et al. . SARS-CoV-2 reinfections: overview of efficacy and duration of natural and hybrid immunity. Environ Res. 2022 Jun;209:112911. doi:10.1016/j.envres.2022.112911</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.envres.2022.112911</ArticleId><ArticleId IdType="pmc">PMC8824301</ArticleId><ArticleId IdType="pubmed">35149106</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca MHG, de Souza TFG, de Carvalho Araujo FM, et al. . Dynamics of antibody response to CoronaVac vaccine. J Med Virol. 2022 May;94(5):2139&#x2013;2148. doi:10.1002/jmv.27604</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27604</ArticleId><ArticleId IdType="pmc">PMC9015561</ArticleId><ArticleId IdType="pubmed">35060174</ArticleId></ArticleIdList></Reference><Reference><Citation>Saure D, O'Ryan M, Torres JP, et al. . Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study. Lancet Infect Dis. 2022 Jan;22(1):56&#x2013;63. doi:10.1016/S1473-3099(21)00479-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00479-5</ArticleId><ArticleId IdType="pmc">PMC8428469</ArticleId><ArticleId IdType="pubmed">34509185</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh AK, Phatak SR, Singh R, et al. . Humoral antibody kinetics with ChAdOx1-nCOV (covishield) and BBV-152 (covaxin) vaccine among Indian healthcare workers: A 6-month longitudinal cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study. Diabetes Metab Syndr. 2022 Feb;16(2):102424. doi:10.1016/j.dsx.2022.102424</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2022.102424</ArticleId><ArticleId IdType="pmc">PMC8816907</ArticleId><ArticleId IdType="pubmed">35150961</ArticleId></ArticleIdList></Reference><Reference><Citation>Di D, Shi F, Yan F, et al. . Hypergraph learning for identification of COVID-19 with CT imaging. Med Image Anal. 2021 Feb;68:101910. doi:10.1016/j.media.2020.101910</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.media.2020.101910</ArticleId><ArticleId IdType="pmc">PMC7690277</ArticleId><ArticleId IdType="pubmed">33285483</ArticleId></ArticleIdList></Reference><Reference><Citation>Maestre-Muniz MM, Arias A, Mata-Vazquez E, et al. . Long-Term outcomes of patients with coronavirus disease 2019 at One year after hospital discharge. J Clin Med. 2021 Jun 30;10(13):2945. doi:10.3390/jcm10132945</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10132945</ArticleId><ArticleId IdType="pmc">PMC8269002</ArticleId><ArticleId IdType="pubmed">34209085</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Li X, Gu X, et al. . Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. The Lancet Respiratory Medicine. 2022 Sep;10(9):863&#x2013;876. doi:10.1016/S2213-2600(22)00126-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00126-6</ArticleId><ArticleId IdType="pmc">PMC9094732</ArticleId><ArticleId IdType="pubmed">35568052</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang XY, Hou C, Shen Y, et al. . Two-Year health outcomes in hospitalized COVID-19 survivors in China. Jama Netw Open. 2022 Sep 1;5(9):e2231790. doi:10.1001/jamanetworkopen.2022.31790</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.31790</ArticleId><ArticleId IdType="pmc">PMC9478774</ArticleId><ArticleId IdType="pubmed">36107425</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang CL, Huang LX, Wang YM, et al. . 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study (publication with expression of concern. See vol. 401, pg. 90, 2023). Lancet. 2021 Jan 16;397(10270):220&#x2013;232. doi:10.1016/S0140-6736(20)32656-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellan M, Soddu D, Balbo PE, et al. . Respiratory and psychophysical sequelae Among patients With COVID-19 four months after hospital discharge. Jama Netw Open. 2021 Jan 27;4(1). doi:10.1001/jamanetworkopen.2020.36142</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.36142</ArticleId><ArticleId IdType="pmc">PMC7841464</ArticleId><ArticleId IdType="pubmed">33502487</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg B, Mohn KGI, Brokstad KA, et al. . Long COVID in a prospective cohort of home-isolated patients. Nat Med. 2021 Sep;27(9):1607. doi:10.1038/s41591-021-01433-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01433-3</ArticleId><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference><Reference><Citation>Martimbianco ALC, Pacheco RL, Bagattini AM, et al. . Frequency, signs and symptoms, and criteria adopted for long COVID-19: A systematic review. Int J Clin Pract. 2021 Oct;75(10):e14357. doi:10.1111/ijcp.14357</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.14357</ArticleId><ArticleId IdType="pmc">PMC8236920</ArticleId><ArticleId IdType="pubmed">33977626</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker M, Elliott J, Chadeau-Hyam M, et al. . Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nat Commun. 2022 Apr 12;13(1):1957. doi:10.1038/s41467-022-29521-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-29521-z</ArticleId><ArticleId IdType="pmc">PMC9005552</ArticleId><ArticleId IdType="pubmed">35413949</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans RA, Leavy OC, Richardson M, et al. . Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Resp Med. 2022 Aug;10(8):761&#x2013;775. doi:10.1016/S2213-2600(22)00127-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00127-8</ArticleId><ArticleId IdType="pmc">PMC9034855</ArticleId><ArticleId IdType="pubmed">35472304</ArticleId></ArticleIdList></Reference><Reference><Citation>de Erausquin GA, Snyder H, Carrillo M, et al. . The chronic neuropsychiatric sequelae of COVID-19: The need for a prospective study of viral impact on brain functioning. Alzheimers Dement. 2021 Jun;17(6):1056&#x2013;1065. doi:10.1002/alz.12255</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12255</ArticleId><ArticleId IdType="pmc">PMC10431934</ArticleId><ArticleId IdType="pubmed">33399270</ArticleId></ArticleIdList></Reference><Reference><Citation>Song WJ, Hui CKM, Hull JH, et al. . Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses. Lancet Resp Med. 2021 May;9(5):533&#x2013;544. doi:10.1016/S2213-2600(21)00125-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00125-9</ArticleId><ArticleId IdType="pmc">PMC8041436</ArticleId><ArticleId IdType="pubmed">33857435</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong SJ. Persistent brainstem dysfunction in long-COVID: A hypothesis. Acs Chem Neurosci. 2021 Feb 17;12(4):573&#x2013;580. doi:10.1021/acschemneuro.0c00793</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.0c00793</ArticleId><ArticleId IdType="pubmed">33538586</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostergaard L. SARS CoV-2 related microvascular damage and symptoms during and after COVID-19: consequences of capillary transit-time changes, tissue hypoxia and inflammation. Physiol Rep. 2021 Feb;9(3. doi:10.14814/phy2.14726</Citation><ArticleIdList><ArticleId IdType="doi">10.14814/phy2.14726</ArticleId><ArticleId IdType="pmc">PMC7849453</ArticleId><ArticleId IdType="pubmed">33523608</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedj E, Campion JY, Dudouet P, et al. . F-18-FDG brain PET hypometabolism in patients with long COVID. Eur J Nucl Med Mol I. 2021 Aug;48(9):2823&#x2013;2833. doi:10.1007/s00259-021-05215-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-021-05215-4</ArticleId><ArticleId IdType="pmc">PMC7837643</ArticleId><ArticleId IdType="pubmed">33501506</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhawan RT, Gopalan D, Howard L, et al. . Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19. Lancet Resp Med. 2021 Jan;9(1):107&#x2013;116. doi:10.1016/S2213-2600(20)30407-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30407-0</ArticleId><ArticleId IdType="pmc">PMC7833494</ArticleId><ArticleId IdType="pubmed">33217366</ArticleId></ArticleIdList></Reference><Reference><Citation>Clough E, Chean KT, Inigo J, et al. . Mitochondrial dynamics in SARS-COV2 spike protein treated human microglia: implications for neuro-COVID. J Neuroimmune Pharm. 2021 Dec;16(4):770&#x2013;784. doi:10.1007/s11481-021-10015-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-021-10015-6</ArticleId><ArticleId IdType="pmc">PMC8487226</ArticleId><ArticleId IdType="pubmed">34599743</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefano GB, Ptacek R, Ptackova H, et al. . Selective neuronal mitochondrial targeting in SARS- CoV-2 infection affects cognitive processes to induce &#x2018;brain fog&#x2019; and results in behavioral changes that favor viral survival. Med Sci Monitor. 2021 Jan 25;27:e930886. doi:10.12659/MSM.930886</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.930886</ArticleId><ArticleId IdType="pmc">PMC7845145</ArticleId><ArticleId IdType="pubmed">33487628</ArticleId></ArticleIdList></Reference><Reference><Citation>Eythorsson E, Runolfsdottir HL, Ingvarsson RF, et al. . Rate of SARS-CoV-2 reinfection during an omicron wave in Iceland. Jama Netw Open. 2022 Aug 3;5(8). doi:10.1001/jamanetworkopen.2022.25320</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.25320</ArticleId><ArticleId IdType="pmc">PMC9350711</ArticleId><ArticleId IdType="pubmed">35921113</ArticleId></ArticleIdList></Reference><Reference><Citation>Keeling MJ. Patterns of reported infection and reinfection of SARS-CoV-2 in England. J Theor Biol. 2023 Jan 7;556. doi:10.1016/j.jtbi.2022.111299</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtbi.2022.111299</ArticleId><ArticleId IdType="pmc">PMC9568275</ArticleId><ArticleId IdType="pubmed">36252843</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H, Ayoub HH, Tang PT, et al. . Immune imprinting and protection against repeat reinfection with SARS-CoV-2. New Engl J Med. 2022 Nov 3;387(18):1716&#x2013;1718. doi:10.1056/NEJMc2211055</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2211055</ArticleId><ArticleId IdType="pmc">PMC9634858</ArticleId><ArticleId IdType="pubmed">36223534</ArticleId></ArticleIdList></Reference><Reference><Citation>Malato J, Ribeiro RM, Fernandes E, et al. . Stability of hybrid versus vaccine immunity against BA.5 infection over 8 months. Lancet Infect Dis. 2023 Feb;23(2):148&#x2013;150. doi:10.1016/S1473-3099(22)00833-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00833-7</ArticleId><ArticleId IdType="pmc">PMC9815828</ArticleId><ArticleId IdType="pubmed">36620968</ArticleId></ArticleIdList></Reference><Reference><Citation>dos Santos LA, de Gois PG, Silva AMF, et al. . Recurrent COVID-19 including evidence of reinfection and enhanced severity in thirty Brazilian healthcare workers. J Infection. 2021 Mar;82(3):399&#x2013;406. doi:10.1016/j.jinf.2021.01.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.01.020</ArticleId><ArticleId IdType="pmc">PMC7880834</ArticleId><ArticleId IdType="pubmed">33589297</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelrahman MM, Abd-Elrahman NM, Bakheet TM.. Persistence of symptoms after improvement of acute COVID19 infection, a longitudinal study. J Med Virol. 2021 Oct;93(10):5942&#x2013;5946. doi:10.1002/jmv.27156</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27156</ArticleId><ArticleId IdType="pmc">PMC8426945</ArticleId><ArticleId IdType="pubmed">34171139</ArticleId></ArticleIdList></Reference><Reference><Citation>Bechmann N, Barthel A, Schedl A, et al. . Sexual dimorphism in COVID-19: potential clinical and public health implications. Lancet Diabetes Endo. 2022 Mar;10(3):221&#x2013;230. doi:10.1016/S2213-8587(21)00346-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(21)00346-6</ArticleId><ArticleId IdType="pmc">PMC8803381</ArticleId><ArticleId IdType="pubmed">35114136</ArticleId></ArticleIdList></Reference><Reference><Citation>Hastie CE, Lowe DJ, McAuley A, et al. . Outcomes among confirmed cases and a matched comparison group in the long-COVID in Scotland study (vol 13, 5663, 2022). Nat Commun. 2022 Oct 12;13(1):5663. doi:10.1038/s41467-022-33415-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33415-5</ArticleId><ArticleId IdType="pmc">PMC9556711</ArticleId><ArticleId IdType="pubmed">36224173</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehandru S, Merad M.. Pathological sequelae of long-haul COVID. Nat Immunol. 2022 Feb;23(2):194&#x2013;202. doi:10.1038/s41590-021-01104-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01104-y</ArticleId><ArticleId IdType="pmc">PMC9127978</ArticleId><ArticleId IdType="pubmed">35105985</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiyegbusi OL, Hughes SE, Turner G, et al. . Symptoms, complications and management of long COVID: a review. J Roy Soc Med. 2021 Sep;114(9):428&#x2013;442. doi:10.1177/01410768211032850</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/01410768211032850</ArticleId><ArticleId IdType="pmc">PMC8450986</ArticleId><ArticleId IdType="pubmed">34265229</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>